Suhail Ahmed Almani, Noor Muhammad Memon, Abdul Fateh Qureshi.
Drug - Resistant Tuberculosis in Sindh.
J Coll Physicians Surg Pak Jan ;12(3):136-9.

Objective: To assess the prevalence of primary and secondary drug resistance amongst the clinical isolates of M. tuberculosis, to identify risk factors and how to overcome this problem. Design: A case series of 50 indoor patients with sputum smear-positive pulmonary tuberculosis. Place and Duration of Study: Department of Medicine, Liaquat University of Medical and Health Sciences Jamshoro, Sindh, (Pakistan) from January 1999 to December 2000. Patients and Methods: Four first line anti-tuberculous drugs, isoniazid, rifampicin, ethambutol and streptomycin were tested for sensitivity pattern. Results: Twelve (26.66%) were sensitive to all four drugs, 12 (26.66%) were resistant to one drug, 14 (31.11%) were resistant to two drugs, 2 (4.44%) were resistant to three drugs, and 5 (11.11%) were resistant to all four drugs. Resistance to isoniazid was the most common in 27 cases (60%) with primary resistance in 6 (13.33%) and secondary resistance in 21(46.66%), followed by resistance to streptomycin in 17 cases (37.77%) with primary resistance in 5 (11.11%) and secondary resistance in 12 (26.66%). Resistance to ethambutol in 10 cases (22.22%) and rifampicin in 11 (24.44%) and all cases were secondary. Similarly multi-drug resistant (MDR) TB was found in 11(24.44%) isolates. Conclusion: This study showed high prevalence of drug resistance among clinical isolates of M. tuberculosis. There is a need to establish centers at number of places with adequate facilities for susceptibility testing so that the resistant pattern could be ascertained and treatment regimens tailored accordingly.

USER COMMENTS

THIS STUDY SHOWS THAT "DOTS"IS VERY MUCH NEEDED THERE.IREQUEST TO THE HEALTH MINISTRY TO DO AT HIS BEST,OTHERWISE THE LIFE OF MANY PEOPLE WILL BE RUINED. MANY THANKS
Posted by: on Jun 2002

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com